Prevention: Aspirin in primary prevention—good news and bad news

[1]  Adrian V. Hernández,et al.  Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. , 2012, Archives of internal medicine.

[2]  N. Sattar,et al.  Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. , 2012, Archives of internal medicine.

[3]  S. Yusuf,et al.  Newly identified events in the RE-LY trial. , 2010, The New England journal of medicine.

[4]  R. Collins,et al.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials , 2009, The Lancet.

[5]  B. Yawn,et al.  Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. , 2009 .

[6]  Alessandro Filippi,et al.  Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins , 2007, Trials.

[7]  J. Gibbs,et al.  JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice , 2005, Heart.

[8]  Diabetes Uk,et al.  JBS 2: Joint British Societies9 guidelines on prevention of cardiovascular disease in clinical practice , 2005 .

[9]  W. Weaver,et al.  Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial , 2003, The Lancet.

[10]  A. Mattioli,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[11]  R. Peto,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[12]  S. Connolly,et al.  Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. , 2011, The Canadian journal of cardiology.

[13]  C. Hennekens,et al.  Sex-related differences in response to aspirin in cardiovascular disease: an untested hypothesis , 2006, Nature Clinical Practice Cardiovascular Medicine.

[14]  Nelson.  Asprin in reducing events in the elderly - ASPREE , 2006 .

[15]  J. McNeil,et al.  Rationale for a Trial of Low-Dose Aspirin for the Primary Prevention of Major Adverse Cardiovascular Events and Vascular Dementia in the Elderly , 2003, Drugs & aging.